FHL5

Across TCGA pan-cancer cohorts, FHL5 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of FHL5’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where FHL5 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types FHL5 is over-expressed in tumor, although a few such as HNSC and LSCC show the opposite, repressed pattern.

HNSC, LSCC, and LUAD are the cancer types where FHL5 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FHL5 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	−1.566	<.001	11	view →
LSCC	Male	II,III,IV	−2.321	<.001	9	view →
LUAD	Female	II,III,IV	−1.917	<.001	9	view →
PDAC	All	II,III,IV	−0.472	.001	8	view →
CCRCC	Male	III,IV	−0.577	<.001	6	view →
COAD	Female	All	−0.707	.017	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

FHL5–HNSC

Open the HNSC breakdown →